How to work together

We are looking for partners to support and help drive the development of animal-derived ingredients and compounds in the pharmaceutical, food, animal feed and agricultural sectors. Specifically, we actively research new ingredients in glycosaminoglycans, complex lipids and non-recombinant proteins (including bioactive peptides and enzymes) and other high-value biological molecules such as hormones.

We believe that partnership is an open and honest collaboration, an effective means of accelerating the development and delivery of new and innovative products. We seek complementary partnerships, a mutually beneficial relationship achieved through shared objectives, strategies and timelines. Our partners facilitate the progress of projects in unique fields that require supply potential, additional scientific knowledge, analytical resources, processes and regulatory expertise.

There are two types:

• Scientific / technological partnerships: to discover knowledge in new areas or incorporate new technologies.
• Companies with final dosage forms: final product development, market access, joint investment.

We have established, and also actively seek, partnerships with clients and suppliers from pharmaceutical, food, start-up, biotech and scientific companies.

We have more than 50 years of experience in the development and characterisation of complex ingredients and APIs, under GLP and GMP criteria, for clinical and pre-clinical trials. Our integrated business model and supply chain, controlled from animal to final ingredient, means that we are the specialist who can secure any animal-derived raw material under the strictest standards of quality, safety and traceability. This unique approach allows us to support our partners in all phases of the process, from sourcing raw materials to product development and analysis.

Our partnership strategy allows for continued success by reducing the uncertainties inherent in new projects. By sharing expertise, assets and capabilities with our partners, we accelerate the speed and development of these projects and can make decisions with less risk. These well-established practices allow for a faster and more secure return on investment and support the long-term growth of both companies.

When assessing a potential partnership, we look at how we can contribute to global growth, for example, whether there are sustainable competitive advantages and opportunities for long-term success. 

When deciding whether to work with a potential partner, we assess the compatibility of the two companies, the alignment of objectives and strategies, timelines, risks of forming an exclusive partnership and any other intangible aspects that may affect the success of the relationship.

We are an open and flexible company, always looking for creative ways to collaborate with our partners. As a starting point, we seek to identify opportunities in the market that have not yet been covered and/or have high growth potential. Our partnership model is initially based on an analysis of the strengths and weaknesses of each company. When a related interest is identified, we establish a non-binding term sheet to proceed with our due diligence process and structure a formalised agreement. We want to create a win-win solution for both our company and our partners so each agreement is structured to ensure a return on investment for both parties. This approach allows us to build the trust necessary for a lasting and fruitful partnership.

One of the most challenging aspects of product innovation in medicines or complex ingredients is product characterisation. Although the authorities are willing to introduce generic versions of older but effective products, the intrinsic characteristics of the manufacturing process and the variability of biological tissues may make this characterisation difficult to demonstrate. With our expertise in product determination, we support our partners, using knowledge of glycosaminoglycans, proteins and complex lipids, to overcome these challenges using orthogonal and complementary analytical techniques.

We also ensure that safety, reliability and resource scarcity are taken into account at this stage. This is particularly important when considering the biological risks associated with any natural source, or more specifically those derived from animals. At Bioiberica and Saria we have a system that guarantees full traceability of raw materials, together with an exhaustive quality policy and a testing process that certifies the safety of any new ingredient.

Another challenge affecting not only the pharmaceutical industry but also the food, animal feed and agriculture industries is the increasingly restrictive regulatory framework affecting animal-derived products. With several years of experience, our regulatory team overcomes these obstacles with creative and practical solutions based on extensive knowledge of guidelines and objective supporting data.

Our R&D Innovation Partnership department is dedicated to identifying growth opportunities and ways to meet, discuss and develop ideas with potential partners. Once a project begins to take shape, we bring in other professionals from relevant areas of the company who remain engaged throughout the process.